Ionis Pharmaceuticals and its partner Roche announced positive Phase 3 IMAgINATION study results for sefaxersen in patients with IgA nephropathy. The trial met its primary endpoint, demonstrating a statistically significant 43.1% reduction in proteinuria compared to placebo at 37 weeks, with a safety profile consistent with earlier studies.
Counterparty
Roche
“These data support our belief that sefaxersen is uniquely positioned to treat IgA nephropathy, demonstrating significant and clinically meaningful reduction in proteinuria and offering the potential to help reduce the need for long-term dialysis or kidney transplantation.”
Brett P. Monia, Ph.D., chief executive officer, Ionis
“Sefaxersen is a powerful example of the broad impact of Ionis' innovative science, and based on these positive data, we believe it has the potential to be an important new treatment option for people living with IgA nephropathy.”
Brett P. Monia, Ph.D., chief executive officer, Ionis
Ionis Pharmaceuticals' partner GSK received FDA approval for HIBSAGO (bepirovirsen) for the treatment of chronic hepatitis B (CHB) in adult patients without cirrhosis. The approval, granted under priority review and Breakthrough Therapy Designation, is based on Phase 3 B-Well trials showing a 19% functional cure rate compared to less than 1% for standard of care. Ionis is eligible to receive regulatory and sales milestone payments plus tiered royalties of 10-12% on net sales.
Ionis and partner Roche announced positive interim results from the Phase 3 IMAgINATION study of sefaxersen in adults with IgA nephropathy (IgAN). The study met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in proteinuria compared to placebo at 37 weeks.
Counterparty
Roche Holding Ltd.
“With these positive interim results, sefaxersen is positioned to directly address a primary driver of IgAN-related kidney damage, offering the potential to help slow disease progression and potentially reduce the long-term need for dialysis or kidney transplantation.”
Brett P. Monia, Ph.D., chief executive officer, Ionis